NCT05976139
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies
At risk: Primary completion moved 1 year 5 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jul 30, 2025 to Dec 30, 2026 Show 6 more changesShow less
- Eligibility criteria expanded, about 17 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 1 of 3 entries
- Study description revised
- Site details revised
- Publications: details revised at 15 of 15 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 25, 2023 to Sep 6, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Laser treatment will be performed in patients with macular edema in IRD (experimental arm) who: * underwent treatment with diuretics or nutritional drainage products for 3 months and subsequent 'wash-out' of one month 17,18 and had no reduction in macular oedema, in terms of central retinal thickness, of at least 20% compared with the initial assessment * they have had an intravitreal injection of anti-VEGF or steroids, and after 3 months there is no reduction in central retinal thickness (CRT) of at least 20% compared to the initial assessment * have after 3 months a thickness reduction \<10% compared to baseline assessment, following initial treatment with micropulsed laser, and may be candidates for repeating treatment; * are not eligible for diuretic therapy due to the presence of comorbidities.
Devices: subthreshold treatment with micropulsed laser
Sites
1 site in 1 country
- IRCSS Fondazione G:B:BiettiRome, RM, Italy